Literature DB >> 35034258

Genetic Variation in ATXN3 (Ataxin-3) 3'UTR: Insights into the Downstream Regulatory Elements of the Causative Gene of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3.

Ana Rosa Vieira Melo1,2, Mafalda Raposo3,4, Marta Ventura5, Sandra Martins6,7, Sara Pavão3, Isabel Alonso4, Conceição Bettencourt8, Manuela Lima3,4.   

Abstract

Untranslated regions are involved in the regulation of transcriptional and post-transcriptional processes. Characterization of these regions remains poorly explored for ATXN3, the causative gene of Machado-Joseph disease (MJD). Although a few genetic modifiers have been identified for MJD age at onset (AO), they only explain a small fraction of the AO variance. Our aim was to analyse variation at the 3'UTR of ATXN3 in MJD patients, analyse its impact on AO and attempt to build haplotypes that might discriminate between normal and expanded alleles.After assessing ATXN3 3'UTR variants in molecularly confirmed MJD patients, an in silico analysis was conducted to predict their functional impact (e.g. their effect on miRNA-binding sites). Alleles in cis with the expanded (CAG)n were inferred from family data, and haplotypes were built. The effect of the alternative alleles on the AO and on SARA and NESSCA ataxia scales was tested.Nine variants, all previously described, were found. For eight variants, in silico analyses predicted (a) deleterious effects (rs10151135; rs55966267); (b) changes on miRNA-binding sites (rs11628764; rs55966267; rs709930) and (c) alterations of RNA-binding protein (RBP)-binding sites (rs1055996; rs910369; rs709930; rs10151135; rs3092822; rs7158733). Patients harbouring the alternative allele at rs10151135 had significantly higher SARA Axial subscores (p = 0.023), comparatively with those homozygous for the reference allele. Ten different haplotypes were obtained, one of which was exclusively found in cis with the expanded and four with the normal allele. These findings, which are relevant for the design of allele-specific therapies, warrant further investigation in independent MJD cohorts.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gametic phase; Genetic modifiers; MJD; Polyglutamine disease; SCA3; Transcription regulation; Untranslated regions; miRNA

Year:  2022        PMID: 35034258     DOI: 10.1007/s12311-021-01358-0

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  24 in total

Review 1.  Machado-Joseph Disease: from first descriptions to new perspectives.

Authors:  Conceição Bettencourt; Manuela Lima
Journal:  Orphanet J Rare Dis       Date:  2011-06-02       Impact factor: 4.123

2.  Replicating studies of genetic modifiers in spinocerebellar ataxia type 3: can homogeneous cohorts aid?

Authors:  Mafalda Raposo; Amanda Ramos; Conceição Bettencourt; Manuela Lima
Journal:  Brain       Date:  2015-07-14       Impact factor: 13.501

3.  Characterization and evolution of 5' and 3' untranslated regions in eukaryotes.

Authors:  Honglei Liu; Jiaming Yin; Meili Xiao; Caihua Gao; Annaliese S Mason; Zunkang Zhao; Yingchun Liu; Jiana Li; Donghui Fu
Journal:  Gene       Date:  2012-07-27       Impact factor: 3.688

Review 4.  Understanding Neurodevelopmental Disorders: The Promise of Regulatory Variation in the 3'UTRome.

Authors:  Kai A Wanke; Paolo Devanna; Sonja C Vernes
Journal:  Biol Psychiatry       Date:  2017-11-14       Impact factor: 13.382

5.  The APOE ε2 allele increases the risk of earlier age at onset in Machado-Joseph disease.

Authors:  Conceição Bettencourt; Mafalda Raposo; Nadiya Kazachkova; Teresa Cymbron; Cristina Santos; Teresa Kay; João Vasconcelos; Patrícia Maciel; Karina C Donis; Maria Luiza Saraiva-Pereira; Laura B Jardim; Jorge Sequeiros; Manuela Lima
Journal:  Arch Neurol       Date:  2011-12

6.  The genomic structure and expression of MJD, the Machado-Joseph disease gene.

Authors:  Y Ichikawa; J Goto; M Hattori; A Toyoda; K Ishii; S Y Jeong; H Hashida; N Masuda; K Ogata; F Kasai; M Hirai; P Maciel; G A Rouleau; Y Sakaki; I Kanazawa
Journal:  J Hum Genet       Date:  2001       Impact factor: 3.172

7.  Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3).

Authors:  Conceição Bettencourt; Cristina Santos; Rafael Montiel; Maria do Carmo Costa; Pablo Cruz-Morales; Liliana Ribeiro Santos; Nelson Simões; Teresa Kay; João Vasconcelos; Patrícia Maciel; Manuela Lima
Journal:  Neurogenetics       Date:  2009-08-28       Impact factor: 2.660

8.  Variation in DNA Repair System Gene as an Additional Modifier of Age at Onset in Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.

Authors:  Rafaella Mergener; Gabriel Vasata Furtado; Eduardo Preusser de Mattos; Vanessa Bielefeldt Leotti; Laura Bannach Jardim; Maria Luiza Saraiva-Pereira
Journal:  Neuromolecular Med       Date:  2019-10-05       Impact factor: 3.843

9.  Genetic risk factors for modulation of age at onset in Machado-Joseph disease/spinocerebellar ataxia type 3: a systematic review and meta-analysis.

Authors:  Eduardo Preusser de Mattos; Maiara Kolbe Musskopf; Vanessa Bielefeldt Leotti; Maria Luiza Saraiva-Pereira; Laura Bannach Jardim
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-10-18       Impact factor: 10.154

10.  Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA.

Authors:  Kirtika H Asrani; Jeremiah D Farelli; Mary R Stahley; Rebecca L Miller; Christopher J Cheng; Romesh R Subramanian; Jeffrey M Brown
Journal:  RNA Biol       Date:  2018-03-26       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.